The Paragard lawsuit centers on claims tied to a copper intrauterine device used by millions of patients across the United States. Plaintiffs say the Paragard IUD fractured during removal. Patients describe severe pain. Patients describe internal injuries. Lawsuits say medical providers needed surgery to retrieve broken device fragments. Courts began to see steady filings after similar accounts appeared nationwide. Public records show a pattern that drew federal attention.
The litigation matters because Paragard stands as the only hormone-free IUD approved for long-term use in the United States. Doctors marketed the device as safe. Patients relied on that promise. Lawsuits now challenge the design. Complaints say the device arms can break without warning. Complaints also say the risk appeared higher during routine removal. The claims raised questions about testing and warnings.
Federal courts consolidated cases to manage the volume. Judges now oversee discovery and expert disputes. Defense lawyers deny wrongdoing. Plaintiffs continue to press claims of design defect and failure to warn. The litigation remains active in 2025.
How the Paragard Lawsuit Started
Early lawsuits described a similar event. A patient sought routine removal. The device fractured. Medical records later showed retained fragments. Some patients needed a hysteroscopy. Some patients needed laparoscopic surgery. Court filings show doctors sometimes failed to locate missing pieces during the first attempt. Pain followed. Anxiety followed. Costs followed.
Plaintiffs later connected experiences through legal intake campaigns and news reporting. Law firms reviewed operative notes and pathology reports. Complaints alleged the copper arms lacked adequate flexibility. Complaints alleged the manufacturer failed to redesign the product despite earlier signals. Filings appeared in multiple districts. Federal consolidation followed.
Background of the Case
Paragard entered the U.S. market decades ago. Regulators cleared the device under standards that applied at the time. Marketing materials emphasized durability. Instructions described routine insertion and removal. Litigation later focused on real-world performance during removal. Plaintiffs say the arms can embed in the uterine wall. Plaintiffs say traction during removal can cause snapping.
Ownership history also became part of the record. Teva Pharmaceuticals once sold Paragard. Later, control transferred to CooperSurgical. Defense filings say the device met regulatory requirements. Defense filings say reported breakage rates remain low relative to total use. Courts continue to weigh those positions.
Key Allegations
Plaintiffs allege a defective design. Complaints say the T-shaped arms fail under foreseeable stress. Lawsuits also allege inadequate warnings to doctors and patients. Filings say labeling did not clearly disclose fracture risk during removal. Some complaints include claims for negligent testing and breach of warranty.
Defense responses reject those allegations. Court papers say Paragard underwent appropriate review. Filings say many removals occur without incident. Defense teams argue that patient anatomy and provider technique can affect outcomes. Judges have allowed core claims to proceed while dismissing others.
Timeline of the Paragard Lawsuit
Early Complaints and Consumer Signals
Patient complaints surfaced years before consolidation. Medical literature recorded case reports describing fractured copper arms. Consumer forums later echoed similar experiences. Law firm investigations followed. Source material includes medical case reports and early state court filings.
Company Response
Public statements from the manufacturer emphasized safety and compliance. Defense filings stressed regulatory clearance and long market history. Court records show no recall tied to breakage claims. Source material includes court pleadings and public statements cited in filings.
Court Filings and Legal Steps
The U.S. Judicial Panel on Multidistrict Litigation centralized federal cases in 2021. The panel assigned the litigation to the Northern District of Georgia. The docket received MDL No. 2974. Leigh Martin May oversees the proceedings. Discovery moved forward. Expert challenges followed. Bellwether trials later tested core claims. Source material includes JPML transfer orders and district court dockets.
Judge Notes or Judicial Signals
Court orders reflect scrutiny of expert testimony. Rulings addressed causation standards and admissibility. Some claims are narrowed. Other claims survived. Judges signaled the need for individualized proof in many cases. Source material includes published MDL orders.
Government or Regulatory Actions
Public records show no FDA enforcement action specific to Paragard breakage claims. Regulatory databases continue to accept adverse event reports. Source material includes FDA MAUDE summaries referenced in litigation.
Settlement Timeline
Court records show no global settlement as of 2025. Parties continue to litigate remaining cases. Source material includes MDL status conferences.
Current Status
JPML statistics reports show the Paragard MDL once exceeded three thousand pending cases. Later reports show a reduced docket after dismissals and remands. The litigation remains active with coordinated discovery and case management. Source material includes JPML statistical reports and MDL filings.
Additional Case Details
Some plaintiffs pursue cases outside federal consolidation. State courts continue to see individual actions. Outcomes vary by jurisdiction. Courts assess statute of limitations and proof issues on a case-by-case basis. Lawyers continue to file new cases tied to recent removals. The overall litigation posture remains fluid.
Musarat Bano is a content writer for LegalSever.com who covers lawsuits, legal news, and general legal topics. Her work focuses on research-based, informational content developed from publicly available sources and is intended to support public awareness. She does not provide legal advice or professional legal services.
